

Orange County Employees Retirement System

OCERS - Private Equity

Portfolio Report

As Of December 2025

Report created: July 2026

PRIVATE AND CONFIDENTIAL: These materials are strictly confidential, constitute trade secrets, are intended solely for the use of the individual or entity named herein ("Intended Recipient") and may not be reproduced, distributed, posted electronically or incorporated into other documents in whole or in part except for the personal reference of the Intended Recipient. If you are not the Intended Recipient you are hereby requested to either destroy or return these documents to Aksia LLC, or any of its affiliates.

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
Active											
Abbott Capital Private Equity Investors 2007	2007	0.1%	75.0	74.4	126.3	-	3.5	55.3	3.5	9.9%	1.7x
Abbott Capital Private Equity Investors 2008	2008	0.2%	75.0	74.6	130.0	-	9.1	64.4	9.1	11.8%	1.9x
Abbott Capital Private Equity Investors 2009	2009	0.2%	75.0	74.6	130.3	-	12.1	67.8	12.1	13.0%	1.9x
Abbott Capital Private Equity Investors 2010	2010	0.5%	75.0	74.3	131.7	-	26.8	84.2	26.8	13.9%	2.1x
Abbott Capital Private Equity Investors 2011	2011	0.4%	45.0	44.8	78.4	0.2	20.9	54.3	20.7	15.1%	2.2x
Abbott Capital Private Equity Investors 2012	2012	0.5%	50.0	49.5	81.6	0.5	29.8	61.4	29.3	15.4%	2.2x
Abbott Capital Private Equity Investors 2013	2013	0.5%	45.0	44.6	73.4	0.5	28.6	56.9	28.1	16.4%	2.3x
Abbott Capital Private Equity Investors 2014	2014	0.6%	45.0	44.1	68.1	0.9	35.0	58.1	34.1	16.3%	2.3x
Abbott Capital Private Equity Investors 2015	2015	0.8%	45.0	43.7	54.6	1.4	42.9	52.5	41.5	16.1%	2.2x
Accel-KKR Capital Partners VI	2019	1.0%	50.0	48.8	6.3	1.2	52.7	9.0	51.4	6.0%	1.2x
Accel-KKR Capital Partners VII	2023	0.1%	40.0	7.3	-	32.7	37.8	-2.2	5.1	n.m. ¹	0.7x
Accel-KKR Growth Capital Partners III	2019	0.5%	25.0	27.6	9.4	3.6	31.0	9.2	27.4	8.3%	1.3x
Accel-KKR Growth Capital Partners IV	2021	0.3%	27.0	14.3	-	12.7	28.2	1.2	15.4	3.1%	1.1x
Adams Street - 2007 Non-U.S. Fund	2007	0.0%	17.5	16.6	27.0	0.9	1.0	10.5	0.1	7.7%	1.6x
Adams Street - 2007 U.S. Fund	2007	0.0%	27.5	26.2	52.9	1.3	1.4	26.8	0.2	12.1%	2.0x
Adams Street - 2008 Non-U.S. Fund	2008	0.0%	20.0	18.3	33.7	1.7	2.0	15.7	0.3	10.3%	1.9x
Adams Street - 2008 U.S. Fund	2008	0.0%	25.0	23.3	53.1	1.7	1.9	30.0	0.2	15.7%	2.3x
Adams Street - 2009 Non-U.S. Developed Markets Fund	2009	0.1%	15.0	13.3	22.6	1.7	5.1	12.7	3.5	12.2%	2.0x
Adams Street - 2009 Non-U.S. Emerging Markets	2009	0.0%	5.0	4.6	6.4	0.4	2.4	3.8	2.0	7.7%	1.8x
Adams Street - 2009 U.S. Fund	2009	0.1%	25.0	23.0	47.1	2.1	9.3	31.4	7.3	14.7%	2.4x
Adams Street - 2010 Non-U.S. Developed Markets Fund	2010	0.1%	15.0	13.5	22.4	1.5	5.9	13.3	4.4	12.6%	2.0x

Total Exposure = Unfunded + NAV

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
Adams Street - 2010 Non-U.S. Emerging Markets	2010	0.0%	5.0	4.5	6.3	0.5	2.9	4.2	2.4	8.9%	1.9x
Adams Street - 2010 U.S. Fund	2010	0.2%	25.0	22.0	45.8	3.0	12.6	33.4	9.7	15.7%	2.5x
Adams Street 2007 Direct Fund	2006	0.0%	5.0	4.9	11.8	0.1	0.7	7.5	0.5	11.8%	2.5x
Adams Street 2008 Direct Fund	2007	0.0%	5.0	4.9	12.3	0.1	1.0	8.3	0.9	15.0%	2.7x
Adams Street 2009 Direct Fund	2008	0.0%	5.0	4.9	9.0	0.1	1.0	5.0	0.9	12.7%	2.0x
Adams Street 2010 Direct Fund	2009	0.0%	5.0	4.8	7.9	0.2	1.5	4.4	1.3	11.5%	1.9x
Adams Street 2011 Direct Fund	2010	0.0%	2.0	1.9	3.1	0.1	0.9	2.0	0.8	12.9%	2.1x
Adams Street 2011 Emerging Markets Fund	2011	0.0%	2.0	1.7	3.0	0.3	1.3	2.3	1.0	11.7%	2.3x
Adams Street 2011 Non-US Developed Markets	2011	0.0%	6.0	5.0	8.4	1.0	3.6	6.0	2.6	13.8%	2.2x
Adams Street 2011 U.S. Fund	2011	0.1%	10.0	8.9	17.7	1.3	5.5	13.0	4.1	15.4%	2.5x
Adams Street 2012 Global Fund	2012	0.4%	35.0	32.5	49.8	2.5	23.0	37.8	20.5	12.7%	2.2x
Adams Street 2013 Global Fund	2013	0.4%	25.0	23.2	31.1	1.8	21.6	27.7	19.7	12.5%	2.2x
Adams Street 2014 Global Fund	2014	0.7%	45.0	41.6	54.3	3.4	43.8	53.2	40.4	13.7%	2.3x
Adams Street 2015 Direct Venture/Growth Fund	2014	0.1%	5.0	4.3	1.1	0.7	4.8	0.9	4.2	2.6%	1.2x
Adams Street 2015 Non-US Fund	2015	0.1%	6.0	5.3	7.6	0.7	7.2	8.9	6.5	21.6%	2.7x
Adams Street 2015 US Fund	2015	0.1%	4.0	3.7	4.3	0.3	4.7	5.0	4.4	19.3%	2.4x
Adams Street Co-Investment Fund III A	2014	0.1%	10.0	8.9	16.8	1.1	6.9	13.7	5.9	17.0%	2.5x
Adams Street Global Secondary Fund 5	2012	0.1%	20.0	15.4	17.3	4.6	8.0	5.3	3.4	5.7%	1.3x
Adams Street SMA (1991-2003) - OCERS	1991	0.0%	200.2	209.6	403.8	5.4	5.5	194.3	0.0	27.4%	1.9x
Adams Street Venture/Growth Fund VI	2015	0.6%	35.0	32.8	16.9	2.2	34.3	16.2	32.1	6.2%	1.5x
Advent Global Technology	2019	0.6%	25.0	25.0	3.4	-	32.4	10.8	32.4	8.2%	1.4x
Advent Global Technology II	2021	0.4%	25.0	17.2	-	7.8	30.5	5.5	22.6	11.5%	1.3x
Advent Global Technology III	2025	-	15.0	-	-	15.0	15.0	-	- ²	-	-

Total Exposure = Unfunded + NAV

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
Advent International GPE IX	2019	0.2%	10.0	9.5	3.6	0.5	12.1	5.7	11.7	12.3%	1.6x
Advent International GPE VIII B SMA	2016	0.1%	5.0	5.0	7.4	-	3.0	5.5	3.0	15.4%	2.1x
Advent International GPE X	2022	0.8%	50.0	31.3	0.5	18.7	60.1	10.7	41.4	16.6%	1.3x
Advent International GPE XI	2025	-	65.0	-	-	65.0	65.0	-	- ²	-	-
AI Co-Investment I-A SCSP	2023	0.2%	7.5	7.4	-	0.1	11.9	4.4	11.9	18.7%	1.6x
Alcentra European Direct Lending Fund II LP (Levered)	2015	0.7%	110.0	100.7	104.1	62.8	103.1	43.7	40.3	6.3%	1.4x
Altaris Health Partners V	2020	0.9%	40.0	37.9	0.7	2.1	48.4	9.1	46.3	8.2%	1.2x
Altaris Health Partners VI	2023	-	40.0	-	-	40.0	40.0	-	- ²	-	-
Altor Fund VI	2022	0.5%	49.0	29.3	10.6	29.3	57.8	9.8	28.5	37.4%	1.3x
Altor III Co-Invest	2025	0.2%	10.0	9.7	-	0.5	12.3	2.0	11.7	n.m. ¹	1.2x
American Industrial Partners Fund VIII	2023	0.6%	50.0	28.8	2.3	23.5	57.5	7.5	34.1	n.m. ¹	1.3x
Aphias Capital Fund I-A	2025	0.0%	50.0	-	-	50.0	49.3	-0.7	-0.7	-	-
ArchiMed MED Platform II	2022	0.4%	25.5	15.0	0.1	11.0	30.8	4.8	19.8	18.7%	1.3x
ArchiMed Med Rise	2024	0.0%	16.2	1.5	-	16.1	17.2	-0.4	1.1	n.m. ¹	0.7x
Aurora Co-Invest	2024	0.2%	10.0	10.0	1.5	-	10.6	2.0	10.6	n.m. ¹	1.2x
Battery Ventures Fund XIV	2022	0.3%	20.0	13.2	-	6.8	21.6	1.6	14.8	7.6%	1.1x
Biloxi Co-Investment Partners	2021	0.2%	10.0	7.3	0.0	2.7	14.9	4.9	12.2	12.5%	1.7x
C-Bridge Healthcare Fund V	2021	0.8%	30.0	33.3	5.3	2.2	42.9	12.7	40.7	14.3%	1.4x
Cinven 8 Project Arrow	2023	0.2%	9.3	9.6	-	-	13.2	3.6	13.2	13.8%	1.4x
Cinven Pegasus	2024	0.2%	8.1	8.3	1.6	-	9.9	3.2	9.9	n.m. ¹	1.4x
Clearlake Capital Partners VI	2020	0.7%	30.0	33.2	8.3	1.8	42.0	15.2	40.2	10.1%	1.5x
Clearlake Capital Partners VII	2021	0.6%	40.0	28.7	0.1	11.4	43.1	3.1	31.7	3.7%	1.1x

Total Exposure = Unfunded + NAV

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
Clearlake Capital Partners VIII	2024	0.0%	60.0	4.2	0.0	55.8	58.5	-1.5	2.7	n.m. ¹	0.6x
DBL Partners TIAB 2018	2019	10.8%	30.0	30.3	-	-	581.9	551.6	581.9	52.9%	19.2x
DBL Partners TIAB 2020	2020	7.5%	30.0	30.3	-	-	402.3	372.0	402.3	61.2%	13.3x
Enak Aggregator L.P. Co-Investment	2022	0.3%	10.2	10.2	-	-	16.5	6.3	16.5	13.0%	1.6x
EQT Ventures II	2019	0.4%	20.0	22.0	4.6	2.5	26.7	6.8	24.2	6.7%	1.3x
EQT Ventures III	2022	0.5%	24.9	20.1	-	5.1	33.5	8.3	28.4	20.6%	1.4x
Falcon Co-Investment Partners	2022	0.1%	10.0	7.6	0.0	2.4	10.0	0.0	7.6	0.1%	1.0x
Frozen Investments Collective S.C.A.	2024	0.2%	8.2	8.2	-	-	9.2	1.0	9.2	n.m. ¹	1.1x
FSN Capital Compass I	2022	0.1%	26.6	10.3	-	18.7	24.8	-4.2	6.1	n.m. ¹	0.6x
FSN Capital VI	2020	0.3%	19.4	15.5	0.2	3.0	20.0	1.6	17.0	3.1%	1.1x
GC Creation Fund III	2025	0.0%	20.0	-	-	20.0	19.9	-0.1	-0.1	-	-
General Catalyst Group X - Early Venture	2020	0.3%	9.0	8.8	-	0.2	13.8	4.8	13.6	9.6%	1.5x
General Catalyst Group X - Endurance	2020	0.2%	10.5	10.5	3.3	-	10.7	3.4	10.7	6.1%	1.3x
General Catalyst Group X - Growth Venture	2020	0.4%	15.0	15.0	-	-	21.6	6.6	21.6	7.9%	1.4x
General Catalyst Group XI – Creation LP	2021	0.2%	7.0	6.7	-	0.3	13.1	6.1	12.8	30.9%	1.9x
General Catalyst Group XI – Endurance LP	2021	0.6%	23.5	23.2	0.0	0.3	31.6	8.1	31.3	10.0%	1.3x
General Catalyst Group XI – Ignition LP	2021	0.3%	9.5	8.3	0.0	1.2	14.9	5.4	13.7	17.6%	1.7x
General Catalyst Group XII - Creation	2024	0.3%	10.0	8.3	0.0	1.7	15.9	5.9	14.2	n.m. ¹	1.7x
General Catalyst Group XII - Endurance	2024	0.4%	15.0	13.0	0.0	2.0	21.5	6.5	19.5	n.m. ¹	1.5x
General Catalyst Group XII - Health Assurance	2024	0.1%	5.0	3.7	0.0	1.3	5.5	0.5	4.2	n.m. ¹	1.1x
General Catalyst Group XII - Ignition	2023	0.2%	10.0	7.3	0.0	2.7	12.6	2.6	9.9	n.m. ¹	1.4x
Genstar Capital Partners IX	2019	0.6%	25.0	26.8	28.7	1.8	33.5	33.6	31.7	25.3%	2.3x
Genstar Capital Partners X	2021	0.7%	35.0	35.6	1.5	0.8	40.2	5.2	39.4	5.0%	1.1x

Total Exposure = Unfunded + NAV

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
Genstar Capital Partners XI	2023	0.1%	35.0	4.9	0.4	30.5	36.3	1.3	5.8	28.2%	1.3x
GGV Capital IX	2024	0.3%	24.0	9.4	-	14.6	31.3	7.3	16.6	n.m. ¹	1.8x
GGV Capital IX Plus	2024	0.1%	6.0	2.0	-	4.1	8.6	2.6	4.5	n.m. ¹	2.3x
GGV Capital VII	2019	0.4%	24.0	23.2	1.2	0.8	24.6	1.8	23.8	1.5%	1.1x
GGV Capital VII Plus	2019	0.1%	6.0	5.9	0.6	0.1	6.4	1.0	6.3	2.9%	1.2x
GGV Capital VIII	2021	0.5%	24.0	20.3	-	3.7	29.7	5.7	26.0	7.9%	1.3x
GGV Capital VIII Plus	2021	0.1%	6.0	4.6	-	1.4	8.1	2.1	6.7	13.3%	1.5x
GGV Discovery III	2021	0.1%	10.0	7.3	0.7	2.7	10.2	0.9	7.5	3.7%	1.1x
GGV Discovery IV Asia	2024	0.0%	5.0	0.9	0.0	4.1	5.1	0.1	0.9	n.m. ¹	1.1x
GGV Discovery IV US	2024	0.0%	5.0	2.4	0.0	2.6	5.2	0.2	2.6	n.m. ¹	1.1x
Greenoaks 6	2025	0.1%	20.0	5.2	-	14.8	20.6	0.6	5.7	n.m. ¹	1.1x
Greenoaks Capital Opportunities Fund IV	2021	0.7%	22.0	20.2	6.7	1.8	37.0	21.7	35.2	26.5%	2.1x
Greenoaks Capital Opportunities V	2023	0.4%	20.0	17.5	-	2.5	25.6	5.6	23.1	24.2%	1.3x
H.I.G. Europe Middle Market LBO Fund II (Cayman)	2025	0.0%	48.2	1.3	-	51.5	53.6	0.7	2.0	n.m. ¹	1.6x
H.I.G. Advantage Buyout Fund	2017	0.8%	50.0	54.0	29.4	7.1	48.3	16.7	41.2	8.6%	1.3x
H.I.G. Advantage Buyout II	2022	0.2%	50.0	10.5	2.2	41.4	53.7	3.9	12.3	18.0%	1.4x
H.I.G. Capital Partners VI	2020	0.3%	15.0	15.3	1.6	0.6	16.0	1.7	15.3	5.9%	1.1x
H.I.G. Capital Partners VII	2025	0.0%	45.0	1.1	-	43.9	44.2	-0.8	0.3	n.m. ¹	0.3x
H.I.G. Europe Capital Partners III	2021	0.2%	15.2	7.7	4.3	9.6	22.2	9.1	12.6	40.4%	2.2x
H.I.G. Europe Middle Market LBO Fund	2020	0.7%	38.7	34.2	8.6	10.8	47.3	10.9	36.5	17.3%	1.3x
H.I.G. Matrix Co-Investors	2022	0.0%	10.0	9.9	-	0.1	2.1	-7.9	2.0	-36.1%	0.2x
H.I.G. Meraki Co-Investment	2024	0.3%	10.0	9.9	-	0.1	18.4	8.4	18.3	n.m. ¹	1.9x

Total Exposure = Unfunded + NAV

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
H.I.G. Middle Market LBO Fund III	2019	0.5%	30.0	29.3	12.0	5.5	31.6	8.8	26.0	9.0%	1.3x
H.I.G. Middle Market LBO Fund IV	2022	0.4%	50.0	21.0	0.5	29.4	48.5	-1.3	19.1	-9.2%	0.9x
H.I.G. Small-Cap & Growth Buyout Fund IV	2025	-	30.0	-	-	30.0	30.0	-	- ²	-	-
H.I.G. Starlite-A Co-Investment	2025	0.2%	10.0	9.7	-	0.3	10.0	0.0	9.7	n.m. ¹	1.0x
H.I.G. Technology Partners A	2022	0.1%	18.8	15.1	0.3	4.1	6.9	-12.0	2.8	-40.6%	0.2x
HarbourVest Partners VI - Direct Fund	1999	0.0%	5.0	4.9	4.7	0.1	0.3	0.0	0.2	0.0%	1.0x
Harvest Partners IX	2021	0.6%	75.0	34.0	4.4	45.2	79.4	4.5	34.2	5.9%	1.1x
Harvest Partners VIII	2019	1.4%	75.0	79.5	45.4	7.0	80.6	39.5	73.6	11.4%	1.5x
HealthQuest Partners III	2019	0.4%	25.0	24.3	5.6	1.2	24.5	4.6	23.3	5.0%	1.2x
HealthQuest Partners IV	2023	0.3%	30.0	16.2	5.4	14.0	28.8	4.1	14.9	16.8%	1.3x
Hellman & Friedman Capital Partners IX	2019	0.8%	25.0	26.8	5.8	1.3	43.0	20.7	41.7	13.4%	1.8x
Hellman & Friedman Capital Partners X	2021	1.6%	75.0	74.7	9.4	5.1	90.7	20.3	85.6	8.8%	1.3x
Hellman & Friedman Capital Partners XI	2022	0.0%	50.0	-	-	50.0	49.9	-0.1	-0.1	-	-
Hg Genesis 11 A	2025	-	28.4	-	-	29.4	29.4	-	- ²	-	-
Hg Genesis 9	2020	0.3%	15.0	14.1	5.8	4.4	20.1	7.3	15.6	14.3%	1.5x
HG Mercury 5	2025	-	17.1	-	-	17.6	17.6	-	- ²	-	-
Hg Saturn 3 A	2022	0.3%	25.0	13.2	-	11.8	28.1	3.1	16.3	10.4%	1.2x
Hg Saturn 4 A	2025	0.0%	35.0	0.1	-	34.9	35.5	0.5	0.6	n.m. ¹	7.2x
HgCapital Genesis 10 A	2022	0.2%	14.6	6.9	-	8.5	17.2	1.7	8.7	18.1%	1.2x
HgCapital Saturn Fund 2	2020	0.5%	25.0	24.8	8.3	6.9	33.9	10.5	27.0	13.1%	1.4x
HIG Europe Capital Partners IV Feeder Cayman	2025	-	41.1	-	-	41.1	41.1	-	- ²	-	-
Insight Partners XI	2019	0.6%	20.0	19.5	1.9	0.8	33.7	15.4	33.0	12.6%	1.8x
Insight Partners XII	2021	0.5%	25.0	23.9	0.0	1.1	27.8	2.8	26.7	3.4%	1.1x

Total Exposure = Unfunded + NAV

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
Insight Partners XIII	2024	0.2%	35.0	10.4	0.0	24.6	36.7	1.7	12.1	n.m. ¹	1.2x
Investindustrial Growth III	2022	0.3%	29.1	13.0	-	18.1	34.4	3.3	16.3	21.9%	1.3x
Investindustrial VIII	2024	0.1%	32.4	3.9	0.0	30.9	34.8	-0.1	3.9	n.m. ¹	1.0x
Lightspeed Opportunity Fund III	2024	0.3%	30.0	11.1	-	18.9	36.3	6.3	17.4	n.m. ¹	1.6x
Lightspeed SPV-A	2025	1.1%	13.0	13.3	-	-	58.3	45.0	58.3	n.m. ¹	4.4x
Lightspeed SPV-A 2	2025	0.2%	5.0	5.0	-	-	9.2	4.2	9.2	n.m. ¹	1.8x
Lightspeed Venture Partners Select VI	2025	0.1%	10.0	2.9	-	7.2	12.4	2.4	5.3	n.m. ¹	1.8x
Lightspeed Venture Partners XV-A (Inception)	2025	0.0%	4.5	1.1	-	3.4	4.4	-0.1	1.1	n.m. ¹	0.9x
Lightspeed Venture Partners XV-B (Ignite)	2025	0.1%	5.5	2.0	-	3.5	6.4	0.9	2.9	n.m. ¹	1.4x
Linden Capital Partners VI	2024	0.0%	50.0	-	-	50.0	49.4	-0.6	-0.6	-	-
Mayfield Select II	2021	0.3%	10.0	9.6	-	0.4	14.1	4.1	13.7	15.5%	1.4x
Mayfield Select III	2025	0.1%	17.5	4.0	-	13.5	17.7	0.2	4.2	n.m. ¹	1.0x
Mayfield XVI	2021	0.3%	10.0	8.5	-	1.5	15.7	5.7	14.2	20.8%	1.7x
Mayfield XVII	2024	0.1%	12.5	3.4	-	9.1	13.6	1.1	4.5	n.m. ¹	1.3x
Mesirow Financial Private Equity Fund IV	2006	0.1%	60.0	57.9	107.8	2.1	8.3	56.1	6.2	10.7%	2.0x
Mesirow Financial Private Equity Fund V	2008	0.3%	60.0	57.3	121.7	2.7	20.2	82.0	17.5	15.6%	2.4x
Mesirow Financial Private Equity Fund VI	2013	0.8%	60.0	54.4	98.3	5.6	50.3	88.6	44.7	18.4%	2.6x
Mesirow Financial Private Equity Fund VII-B	2017	1.2%	40.0	39.6	59.4	0.4	67.3	86.7	66.9	27.7%	3.2x
Minerva Partners	2022	0.2%	10.0	9.0	-	1.0	14.1	4.0	13.1	10.0%	1.4x
Monroe Capital Private Credit Fund II	2015	0.2%	70.0	60.5	78.1	10.5	21.0	28.2	10.5	8.9%	1.5x
MPH-COI-NMI (Project Prince)	2022	0.2%	10.0	6.1	-	3.9	15.5	5.5	11.6	23.4%	1.9x
NC Adonis-Co-Invest Beta	2024	0.2%	10.0	10.0	-	-	11.0	1.0	11.0	n.m. ¹	1.1x
NEA 18 Venture Growth Equity	2022	0.4%	18.0	16.2	0.5	1.8	23.8	6.3	22.1	16.5%	1.4x

Total Exposure = Unfunded + NAV

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
NEA 19 Venture Growth Equity	2025	-	20.0	-	-	20.0	20.0	-	- ²	-	-
NEA SH 2025 SPV	2025	0.1%	5.0	5.0	-	-	5.0	0.0	5.0	n.m. ¹	1.0x
New Enterprise Associates 18	2022	0.3%	12.0	7.3	1.2	4.7	19.2	8.4	14.5	40.8%	2.2x
New Enterprise Associates 19	2025	-	20.0	-	-	20.0	20.0	-	- ²	-	-
Nordic Capital Evo II Beta SCSp	2025	0.0%	31.5	-	-	35.2	35.0	-0.3	-0.3	-	-
Nordic Capital Fund XI	2021	1.0%	49.6	42.2	1.8	11.6	63.9	11.8	52.3	23.9%	1.3x
Nordic Capital Fund XII	2025	-	50.7	-	-	50.5	50.5	-	- ²	-	-
Oak HC-FT Partners III	2019	0.7%	25.0	25.1	2.3	2.2	38.3	13.3	36.1	9.5%	1.5x
Oak HC-FT Partners IV	2021	1.3%	50.0	49.7	0.2	0.5	68.2	18.2	67.7	8.9%	1.4x
Oak HC-FT Partners V-A	2022	0.7%	50.0	38.3	7.1	11.7	49.1	6.2	37.3	14.0%	1.2x
Oak HC-FT Partners VI LP	2025	-	50.0	-	-	50.0	50.0	-	- ²	-	-
Oakley Capital VI-B1 SCSp	2025	0.1%	36.3	4.6	0.0	36.4	40.0	-1.0	3.6	n.m. ¹	0.8x
One Rock Capital Partners III	2021	0.7%	50.0	46.4	42.3	12.6	49.0	32.3	36.5	20.8%	1.7x
One Rock Capital Partners IV	2023	0.2%	50.0	13.7	1.9	38.1	51.2	1.3	13.1	n.m. ¹	1.1x
Orchard Landmark	2013	2.2%	120.0	120.0	91.1	-	119.8	91.0	119.8	7.7%	1.8x
Orchard Landmark II	2016	1.3%	100.0	109.7	101.1	91.3	163.3	63.4	72.0	8.7%	1.6x
Orchid Asia VIII	2021	0.3%	30.0	23.7	6.1	11.4	29.2	0.2	17.8	0.5%	1.0x
PAI Partners VIII-1 SCSp	2022	0.5%	49.5	22.1	1.5	29.7	56.1	5.8	26.4	18.1%	1.3x
Pantheon Multi-Strategy 2014 (US) - OCERS 2014	2014	2.0%	100.0	89.7	107.0	10.3	117.8	124.8	107.4	16.3%	2.4x
Pantheon Multi-Strategy 2014 (US) - OCERS 2015	2015	1.3%	75.0	69.1	49.4	5.9	77.5	51.9	71.7	11.8%	1.8x
Pantheon Multi-Strategy 2014 (US) - OCERS 2016	2016	1.7%	75.0	64.4	49.5	10.6	100.8	75.3	90.2	15.8%	2.2x
Pantheon Multi-Strategy 2014 (US) - OCERS 2018	2018	3.5%	110.0	102.7	28.3	7.3	196.7	114.9	189.4	14.9%	2.1x
Project Alpine Co-Invest Fund	2022	0.2%	10.0	10.0	-	-	11.7	1.7	11.7	4.5%	1.2x

Total Exposure = Unfunded + NAV

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
Project Moon	2025	0.2%	9.7	7.5	-	2.4	10.7	0.7	8.2	n.m. ¹	1.1x
Project Stream Co-Invest Fund	2021	0.1%	5.0	5.0	0.0	-	4.9	-0.1	4.9	-0.5%	1.0x
Proofpoint Co-Invest Fund	2021	0.2%	5.0	5.0	0.8	-	9.2	4.9	9.2	17.2%	2.0x
Seventh Cinven Fund	2019	1.1%	50.5	52.2	12.3	5.4	65.9	20.5	60.5	10.5%	1.4x
Spark Capital Growth Fund III	2020	1.3%	33.3	33.3	6.4	-	69.9	43.0	69.9	21.4%	2.3x
Spark Capital Growth Fund IV	2021	1.3%	33.3	30.6	-	2.7	72.9	39.6	70.3	43.6%	2.3x
Spark Capital Growth Fund V	2024	0.5%	33.3	22.5	-	10.8	36.1	2.8	25.3	n.m. ¹	1.1x
Spark Capital VI	2020	0.4%	16.7	14.9	-	1.8	22.3	5.6	20.5	7.8%	1.4x
Spark Capital VII	2021	0.4%	16.7	13.8	-	2.9	24.6	7.9	21.7	19.7%	1.6x
Spark Capital VIII	2024	0.1%	16.7	6.5	-	10.2	16.5	-0.2	6.3	n.m. ¹	1.0x
Stellex Capital Partners II	2020	1.1%	50.0	50.3	10.8	10.7	72.6	22.5	61.9	14.5%	1.4x
Stellex Capital Partners III	2024	0.3%	60.0	16.8	0.1	43.2	57.8	-2.1	14.5	n.m. ¹	0.9x
The Brinson Partnership Fund Trust	1998	0.0%	4.7	4.6	7.4	0.1	0.1	2.9	0.0	7.9%	1.6x
The Brinson Partnership Fund Trust (Secondary)	1998	0.0%	20.0	19.5	19.9	0.0	0.0	0.4	0.0	0.4%	1.0x
The Eighth Cinven Fund	2023	0.3%	65.2	19.1	1.2	51.8	70.5	0.7	18.7	n.m. ¹	1.0x
Thoma Bravo Discover Fund V	2025	0.1%	25.0	3.5	-	21.5	24.9	-0.1	3.4	n.m. ¹	1.0x
Thoma Bravo Fund XIII	2018	1.6%	75.0	92.6	93.5	5.8	92.6	87.7	86.8	21.0%	1.9x
Thoma Bravo Fund XIV	2021	1.5%	75.0	89.8	29.0	8.9	89.4	19.8	80.5	6.1%	1.2x
Thoma Bravo Fund XV	2022	1.7%	75.0	70.9	6.6	10.7	100.0	25.0	89.4	12.6%	1.4x
Thoma Bravo Fund XVI	2025	0.1%	50.0	4.7	-	45.3	49.9	-0.1	4.6	n.m. ¹	1.0x
TPG Healthcare Partners II	2022	0.8%	50.0	31.9	1.9	20.1	60.9	10.8	40.8	n.m. ¹	1.3x
Trident IX	2021	1.0%	50.0	44.5	6.6	12.1	65.6	15.6	53.5	16.2%	1.4x
Trident VIII	2020	1.0%	50.0	49.9	22.7	5.5	61.7	28.9	56.1	11.6%	1.6x

Total Exposure = Unfunded + NAV

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
Trident X US Fund	2025	0.0%	50.0	-	-	50.0	49.6	-0.4	-0.4	-	-
T-VIII Mercury Co-Invest	2021	0.3%	10.0	9.4	4.3	1.0	16.3	10.2	15.3	19.0%	2.1x
Vega Co-Invest	2024	0.2%	7.5	7.5	-	-	10.5	3.0	10.5	n.m. ¹	1.4x
Vista Equity Partners Fund VII	2018	1.5%	75.0	74.9	9.3	9.3	91.4	16.4	82.0	4.5%	1.2x
Vitruvian Investment Partnership IV	2020	0.6%	25.1	23.9	2.1	3.7	36.5	11.0	32.8	12.0%	1.5x
Vitruvian Investment Partnership V	2023	0.4%	40.3	16.2	-	30.0	49.2	3.0	19.2	19.0%	1.2x
WestCap Strategic Operator Fund II	2021	0.5%	25.0	24.3	0.7	0.9	27.9	3.4	27.0	4.5%	1.1x
ZF Co-Invest	2025	0.2%	7.7	7.7	-	0.2	12.9	5.0	12.7	n.m. ¹	1.7x
Total Active	-	100.0%	6,578.4	4,791.8	3,429.2	2,216.4	7,604.3	4,025.3	5,387.9	18.7%	1.8x

Total Exposure = Unfunded + NAV

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
Liquidated											
American Industrial Partners Capital Fund I	1991	-	10.9	10.5	17.9	-	-	7.3	-	13.7%	1.7x
American Industrial Partners Capital Fund II	1995	-	23.3	21.2	15.4	-	-	-5.8	-	-11.6%	0.7x
Asia Pacific Trust	1990	-	4.4	4.4	5.1	-	-	0.7	-	2.3%	1.2x
Castle Harlan Partners II	1992	-	5.9	5.1	9.5	-	-	4.4	- ²	27.9%	1.9x
Cornerstone Equity Investors IV	1996	-	5.0	4.3	3.5	-	-	-0.7	-	-7.8%	0.8x
Cypress Merchant Banking Partners	1995	-	11.0	9.8	3.7	-	-	-6.1	-	-24.1%	0.4x
Gordon+Morris Investment Partnership	1994	-	6.0	6.0	2.5	-	-	-3.5	-	-22.6%	0.4x
HarbourVest International PEP	1990	-	6.0	6.0	10.4	-	-	4.4	-	13.2%	1.7x
HarbourVest International PEP IV	2001	-	10.0	9.8	17.1	-	-	7.3	-	13.8%	1.8x
HarbourVest Partners II	1985	-	10.0	10.0	19.3	-	-	9.3	-	8.5%	1.9x
HarbourVest Partners III	1988	-	5.0	5.0	10.8	-	-	5.8	-	13.9%	2.2x
HarbourVest Partners IV - Direct Fund	1993	-	6.0	6.0	7.4	-	-	1.4	-	5.6%	1.2x
HarbourVest Partners IV - Investment Program	1993	-	4.0	3.8	15.0	-	-	11.2	-	41.8%	4.0x
HarbourVest Partners VI - Buyout Fund	1999	-	10.0	9.6	17.4	-	-	7.8	-	11.7%	1.8x
HarbourVest Partners VI - Partnership Fund	1999	-	15.0	14.7	18.9	-	-	4.2	-	3.6%	1.3x
IMR LTD Partnership	1992	-	5.0	0.5	0.4	-	-	-0.1	-	-11.2%	0.8x
Park Square Capital Credit Opportunities II	2013	-	100.0	91.0	114.4	-	-	23.4	-	5.4%	1.3x
Park Square Credit Opportunities III	2016	-	47.0	45.0	28.7	-	-	-16.3	-	-11.1%	0.6x
Project Finance Fund III	1996	-	5.2	5.2	10.7	-	-	5.5	-	10.4%	2.1x
Prudential Private Equity Investors III	1993	-	5.0	5.0	4.9	-	-	-0.1	-	-0.7%	1.0x
Schroder Ventures International Life Sciences Fund	1994	-	5.0	5.0	8.8	-	-	3.8	-	16.1%	1.8x

Total Exposure = Unfunded + NAV

	Vintage Year	NAV Weight	Total Commitment (mm)	Contributions (mm)	Distributions (mm)	Unfunded Commitment (mm)	Total Exposure (mm)	Gain/Loss (mm)	NAV (mm)	Net IRR	TVPI
Sofinnova Venture Partners VI	1999	-	2.0	2.0	0.3	-	-	-1.7	-	-19.8%	0.1x
TCW Commingled Debt & Royalty III	1991	-	4.8	4.8	6.5	-	-	1.7	-	11.3%	1.3x
TCW Commingled Debt and Royalty Fund IV	1992	-	5.5	5.5	6.2	-	-	0.7	-	6.8%	1.1x
TCW Debt & Royalty Funds VI	1997	-	2.7	2.7	5.0	-	-	2.2	-	21.7%	1.8x
Vega Partners III	1996	-	5.0	5.0	5.4	-	-	0.4	-	1.3%	1.1x
Total Liquidated	-	-	319.7	297.8	365.1	-	-	67.4	-	6.4%	1.2x
OCERS - Private Equity		100.0%	6,898.1	5,089.6	3,794.3	2,216.4	7,604.3	4,092.7	5,387.9	13.9%	1.8x

1. IRR not meaningful for investments held less than 24 months

2. Adjusted for additional contributions and distributions since last valuation, which is prior to the report date.

Total Exposure = Unfunded + NAV

PRIVATE AND CONFIDENTIAL: These materials are strictly confidential and proprietary, intended solely for the use of the individual or entity to which Aksia LLC, Aksia CA LLC, Aksia Chicago LLC, and/or any of their other affiliates, as applicable (collectively, "Aksia") have sent these materials ("Intended Recipient") and constitute Aksia's trade secrets for all purposes, including for purposes of the Freedom of Information Act or any comparable law or regulation of any government, municipality or regulator. These materials may not be reproduced or distributed, posted electronically or incorporated into other documents in whole or in part except for the personal reference of the Intended Recipient. If you are not the Intended Recipient, you are hereby requested to notify Aksia and either destroy or return these documents to Aksia. The Intended Recipient shall not use Aksia's name or logo or explicitly reference Aksia's research and/or advisory services in the Intended Recipient's materials.

NO OFFERING: These materials do not in any way constitute an offer or a solicitation of an offer to buy or sell funds, private investments or securities mentioned herein. These materials are provided only for use in conjunction with Aksia's services, as such services are defined in an executed agreement between Aksia and the Intended Recipient (hereinafter, the "Agreement"). In the event that an executed Agreement does not exist between Aksia and the Intended Recipient, these materials shall not constitute advice or an obligation to provide such services.

RECOMMENDATIONS: Any Aksia recommendation or opinion contained in these materials is a statement of opinion provided in good faith by Aksia and based upon information which Aksia reasonably believes to be true. Recommendations or opinions expressed in these materials reflect Aksia's judgment as of the date shown, and are subject to change without notice. Actual results may differ materially from any forecasts discussed in the materials. Except as otherwise agreed between Aksia and the Intended Recipient, Aksia is under no future obligation to review, revise or update its recommendations or opinions.

NOT TAX, LEGAL OR REGULATORY ADVICE: An investor should consult its tax, legal and regulatory advisors before allocating to a private investment fund or other investment opportunity. Aksia is not providing due diligence or tax advice concerning the tax treatments of an investment or an investor's allocations to such private investment fund or opportunity. Tax treatment depends on the individual circumstances of each client and may be subject to change in the future.

RESPONSIBILITY FOR INVESTMENT DECISIONS: The Intended Recipient is responsible for performing his, her or its own reviews of any funds or other investment vehicles or opportunities described herein including, but not limited to, a thorough review and understanding of each vehicle's or opportunity's offering materials. The Intended Recipient is advised to consult his, her or its tax, legal and compliance professionals to assist in such reviews. For clients who receive non-discretionary advisory or research services from Aksia: the Intended Recipient acknowledges that it (and not Aksia) is responsible for its investment decisions with respect to any investment vehicles or opportunities described herein.

No assurances can be given that a particular investment or portfolio will meet its investment objectives. Any projections, forecasts or market outlooks provided herein should not be relied upon as events which will occur. *Past performance is not indicative of future results.* Use of advanced portfolio construction processes, risk management techniques and proprietary technology does not assure any level of performance or guarantee against loss of capital.

PERFORMANCE DATA: In cases where an investment manager or general partner implements an investment strategy through multiple investment vehicles (for tax purposes, participation in side pockets and new issues, domicile, currency denomination, etc.,) Aksia may use the returns of one class or series of an investment vehicle in a particular program in its reports to represent the returns of all the investment vehicles in such investment program. The returns for the particular class or series used in Aksia's reports may be different from the returns of the class or series in which the Intended Recipient is invested. To obtain the actual performance of the particular class or series in the Intended Recipient's portfolio, the Intended Recipient should contact the investment manager or general partner directly.

RELiance ON THIRD PARTY DATA: These materials reflect and rely upon information provided by fund managers and other third parties which Aksia reasonably believes to be accurate and reliable. Such information may be used by Aksia without independent verification of accuracy or completeness, and Aksia makes no representations as to its accuracy and completeness. For the avoidance of doubt, these materials have not been produced, reviewed, verified or approved by the fund managers and other third parties to which the materials relate. As such, they do not necessarily reflect the views or opinions of such fund managers and third parties. Certain financial metrics presented herein may be adjusted or normalized and are presented as provided to Aksia. Aksia has not independently verified the accuracy, completeness, or basis of such figures. Adjusted metrics may differ materially from those derived from audited financial statements prepared in accordance with GAAP or IFRS and should not be relied upon as such. In addition, any fund IRRs shown are as reported by the manager/administrator or calculated using cash flows provided by the manager/administrator, and may benefit from such fund's use of a subscription line.

RATING DOWNGRADES (LIQUID INVESTMENTS): Aksia client assets, in aggregate, may represent a large percentage of a manager's or fund's assets under management, and, as such, a rating downgrade by Aksia's research teams could result in redemptions or withdrawals that may have an adverse effect on the performance of a fund.

CONFLICTS OF INTEREST DISCLOSURE: Family members of Aksia personnel may from time to time be employed by managers that Aksia recommends to its clients. While this may pose a potential conflict of interest, we monitor such relationships to seek to minimize any impact of such potential conflict.

PRIVATE INVESTMENT FUND DISCLOSURE: Investments in private investment funds and other similar investment opportunities involve a high degree of risk and you could lose all or substantially all of your investment. Any person or institution making such investments must fully understand and be willing to assume the risks involved. Some private investment funds and opportunities described herein may not be suitable for all investors. Such investments or investment vehicles may use leverage, hold significant illiquid positions, suspend redemptions indefinitely, provide no opportunity to redeem, modify investment strategy and documentation without notice, short sell securities, incur high fees and contain conflicts of interests. Such private investment funds or opportunities may also have limited operating history, lack transparency, manage concentrated portfolios, exhibit high volatility, depend on a concentrated group or individual for investment management or portfolio management and lack any regulatory oversight.

For a description of the risks associated with a specific private investment fund or investment opportunity, investors and prospective investors are strongly encouraged to review each private investment fund or opportunity's offering materials which contain a more specific description of the risks associated with each investment. Offering materials may be obtained from the fund manager.

FOR RECIPIENTS OF REPORTS DISTRIBUTED BY AKSIA EUROPE LIMITED: Aksia Europe Limited is authorized and regulated by the Financial Conduct Authority; such authorization does not indicate endorsement or approval by the FCA of the services offered by Aksia.

The Market Abuse Regulation (Regulation (EU) No 596/2014) ("MAR") requires that persons who produce or disseminate investment recommendations or other information recommending or suggesting an investment in financial instruments admitted to trading on an EU market (each a "Recommendation") are required to take reasonable care to ensure that such information is objectively presented, and to disclose their interests or indicate conflicts of interest concerning the financial instruments to which that information relates. Aksia's primary research focus is on private investment funds whose shares are typically not listed on any exchange. Certain private funds may, however, list their shares on an EU market, even though there is typically no secondary market or trading of those shares. Unless stated otherwise, the person or persons responsible for the production of a Recommendation is not aware of any conflicts of interest that may impact the objectivity of any Recommendation. To the extent required by MAR, further information, including information regarding the author(s) of a Recommendation is available upon request at compliance@aksia.com.